---
title: "Obefazimod (ABX464) in Ulcerative colitis: Heterogeneity of treatment effect"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Heterogeneity of treatment effect. Topics: Summary: response by prior advanced therapy exposure, Obefazimod induction: efficacy with and without prior inadequate response to advanced therapy, Obefazimod induction: prior Janus kinase inhibitor failure and number of prior advanced therapies, Obefazimod maintenance: efficacy with and without prior inadequate response to advanced therapy, and 7 further topics. 11 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Summary: response by prior advanced therapy exposure

In the pooled ABTECT induction trials, 47.3% of participants had a prior inadequate response to an advanced therapy (AT-IR). The placebo-adjusted difference in clinical remission at week 8 with obefazimod 50 mg was 10.1% in participants with AT-IR and 22.4% in those without; with 25 mg, the difference was lower than with 50 mg in participants with AT-IR, and the two doses performed similarly in participants without AT-IR. In participants with prior JAK inhibitor failure, the pooled placebo-adjusted difference in clinical response with 50 mg was 34%. In the maintenance trial, clinical remission at Week 52 occurred in 72 of 117 (25 mg) and 62 of 105 (50 mg) participants against 15 of 120 with placebo among AT-IR-naive participants, and in 26 of 76 and 38 of 90 against 5 of 72 among participants with prior AT-IR. In the phase 2b open-label maintenance study, clinical remission at week 96 was 63.8% in participants naive to biologics or JAK inhibitors, and 38.8% of those with prior inadequate response were in clinical remission at both weeks 48 and 96. The same direction of effect is reported for comparators: the ACG 2025 guideline states that patients have higher response and remission rates with their first therapies than after failure of other advanced therapies, and the AGA 2024 guideline places different agents in its higher-efficacy tier for advanced therapy-naive and -exposed patients. In a 2026 network meta-analysis of induction trials, obefazimod and upadacitinib showed the highest efficacy in AT-naive patients, and upadacitinib, ustekinumab, and tofacitinib ranked highest in AT-experienced patients. All obefazimod subgroup p-values are nominal.

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [Abivax press release, UEG late-breaking AT-IR subgroup data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect); [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf); [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/); [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463); [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/); [Olivera et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42838315/)

<a id="topic-2.2.2.3-2"></a>

### Obefazimod induction: efficacy with and without prior inadequate response to advanced therapy

> “Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.”
> “In ABTECT‐1, ABTECT‐2, and pooled, a higher proportion of the AT‐IR‐Yes subgroup receiving Obe‐50 achieved all efficacy measures relative to PBO including clinical remission (Obe‐50‐PBO difference: ABTECT‐1 12.7%, p = 0.0039; ABTECT‐2 7.6%, p = 0.0652, pooled 10.1%, p = 0.0009).”
> “In the AT‐IR‐Yes subgroup, the difference from PBO across all efficacy measures was lower for pts receiving Obe‐25 relative to Obe‐50 (Table 1).”
> “In the AT‐IR‐No subgroup, larger proportions achieved all efficacy measures relative to PBO including clinical remission (Obe‐50‐PBO difference: ABTECT‐1 25.0%, p < 0.0001; ABTECT‐2 19.4%, p = 0.0004; pooled 22.4%, p < 0.0001).”
> “In the subset of pts who failed JAKi, higher proportion of pts receiving Obe‐50 or Obe‐25 achieved clinical response versus PBO. The difference from PBO in clinical response for Obe‐25 and Obe‐50 was similar across lines of treatment, from AT‐IR‐No through 4+ AT‐IRs (Table).”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-2.2.2.3-3"></a>

### Obefazimod induction: prior Janus kinase inhibitor failure and number of prior advanced therapies

> “In participants without prior AT-IR, obefazimod 50mg delivered a placebo-adjusted difference in clinical response of 28% (p<0.0001), and in participants with up to four or more prior AT-IR, a placebo-adjusted difference of 29% (p=0.0242). Treatment with obefazimod 50mg also demonstrated robust clinical response in participants who had previously failed JAK inhibitor therapy, with a placebo-adjusted difference of 34% (p=0.0017).”
> “Of the total pooled population, approximately 47% were classified as having a prior inadequate response to advanced therapy (‘AT-IR Yes’) with approximately 21% having failed to respond to a JAK inhibitor.”

Source: [Abivax press release, UEG late-breaking AT-IR subgroup data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect)

<a id="topic-2.2.2.3-4"></a>

### Obefazimod maintenance: efficacy with and without prior inadequate response to advanced therapy

| Clinical remission at Week 52 | Placebo | Obefazimod 25 mg | Obefazimod 50 mg |
| --- | --- | --- | --- |
| AT-IR naive, n/N | “15/120” | “72/117” | “62/105” |
| Prior AT-IR, n/N | “5/72” | “26/76” | “38/90” |

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

> “50 mg cohort had a higher percentage of patients with prior advanced therapy failure relative to patients on 25 mg and placebo”
> “Placebo-adjusted treatment differences were generally numerically larger in AT-IR naïve vs. with patients with prior ATIR”
> “Clinical remission rates numerically favored both obefazimod doses across 0 to ≥4 prior AT-IR therapies and in JAK-IR patients”
> “P-values are nominal and have not been adjusted for multiplicity; therefore, they should be interpreted as descriptive rather than confirmatory.”

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-2.2.2.3-5"></a>

### Obefazimod phase 2b open-label maintenance: participants naive to or refractory to biologics or JAK inhibitors

> “Among the 98 patients with inadequate response to biologics (anti-TNFα, vedolizumab, ustekinumab) or JAK inhibitors, 74/98 (75.5%) achieved clinical response at week 48 and 66/98 (67.3%) at week 96; 38/98 patients (38.8%) were in clinical remission at both weeks 48 and 96 (Figure 4).”
> “In this subset, clinical remission was achieved by 81/119 patients (68.1%) at week 48 and by 76/119 patients (63.8%) at week 96; 89/119 (74.8%) and 82/119 patients (68.9%) had endoscopic improvement, and 54/119 (45.4%) and 58/119 patients (48.7%) achieved endoscopic remission at weeks 48 and 96, respectively.”
> “Rates of clinical remission, endoscopic improvement, and endoscopic remission at weeks 48 and 96 were numerically higher, from 25% to 33%, in the subgroup of naïve relative to refractory patients.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-2.2.2.3-6"></a>

### Obefazimod long-term extension after dose reduction to 25 mg, by prior advanced therapy

> “Clinical and symptomatic remission were stable regardless of prior AT-IR”
> “Endoscopic improvement was stable over time regardless of prior AT-IR”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-2.2.2.3-7"></a>

### Network meta-analysis including obefazimod, stratified by prior advanced therapy

> “Analyses were stratified by prior exposure to ATs.”
> “In AT-naïve patients, obefazimod and upadacitinib showed the highest efficacy, whereas in AT-experienced patients, upadacitinib, ustekinumab, and tofacitinib ranked highest.”

Source: [Olivera et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42838315/)

<a id="topic-2.2.2.3-8"></a>

### Comparator rankings in biologic-exposed patients: network meta-analyses

> “Overall, upadacitinib (P-score 0.93), tofacitinib (P-score 0.88), and ustekinumab (P-score 0.87) ranked highest in inducing remission in biologic-exposed patients with moderate-to-severely active UC.”

Source: [Ananthakrishnan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12148344/)

> “In the biologic/Janus kinase inhibitor (JAKi)-naïve population, induction studies showed similar clinical response and remission rates across most interventions, with upadacitinib demonstrating significant improvements versus most other interventions.”

Source: [Dignass et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11550281/)

<a id="topic-2.2.2.3-9"></a>

### Guideline efficacy tiers by prior advanced therapy exposure: AGA 2024

> “In adult outpatients with moderate-to-severe UC who are naïve to advanced therapies, the AGA suggests using a HIGHER efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib*, risankizumab, guselkumab) OR an INTERMEDIATE efficacy medication (golimumab, ustekinumab, tofacitinib*, filgotinib*, mirikizumab), rather than a LOWER efficacy medication (adalimumab).”
> “In adult outpatients with moderate-to-severe UC who have previously been exposed to one or more advanced therapies, particularly TNF antagonists, the AGA suggests using a HIGHER efficacy medication (tofacitinib, upadacitinib, ustekinumab) OR an INTERMEDIATE efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a LOWER efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).”
> “In the Phase 3 randomized trial of ozanimod against placebo, ozanimod was significantly more effective than placebo in achieving clinical remission with rates of 23% (vs 7%) and 17% (vs. 8%) in biologic-naïve and single biologic-exposed patients. In contrast, in patients who had been on ≥2 biologics previously, ozanimod was no more effective than placebo (4% vs. 3%) in inducing clinical remission.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.3-10"></a>

### Lower response after prior advanced therapy: ACG 2025

> “Patients with moderately to severely active UC have higher rates of response and remission with their first therapies than after failure of one or more other advanced therapies.”
> “Post hoc subgroup analyses and network meta-analyses provide hypothesis-generating data but are not sufficient to stratify therapies for individual patients.”
> “Similar to other therapies in IBD, patients who are advanced therapy-naive had substantially better results than those who were advanced therapy-experienced, supporting the recommendation to treat earlier.”
> “A post hoc analysis demonstrated that patients who were anti–TNF-naive were more likely to respond to vedolizumab compared with those who had received anti-TNF therapy previously (193).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.3-11"></a>

### Comparator subgroups by prior exposure: ECCO 2026

> “Tofacitinib had broadly similar differences in induction of clinical and endoscopic outcomes compared with placebo in patients with previous anti-TNF agent exposure, although the absolute remission rates achieved were lower.”
> “Although clinical and steroid-free clinical remission rates were numerically lower among patients previously treated with biologics or JAKi, differences versus placebo remained statistically significant.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
